公开(公告)号：US20240226297A9

公开(公告)日：2024-07-11

申请号：US18548481

申请日：2022-03-01

申请人： THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA

发明人： James L. Riley ,  Gavin Ellis

IPC分类号： A61K39/00 ,  C07K14/705 ,  C07K14/725 ,  C07K16/40

CPC分类号： A61K39/46433 ,  A61K39/4611 ,  A61K39/4631 ,  C07K14/7051 ,  C07K14/70517 ,  C07K14/70521 ,  C07K16/40 ,  C07K2317/22 ,  C07K2317/569 ,  C07K2319/02 ,  C07K2319/03 ,  C07K2319/30 ,  C07K2319/33

摘要： The present invention includes compositions and methods for an DPP6 specific chimeric antigen receptor (CAR). In certain embodiments the DPP6 specific CAR is expressed on a T regulatory cell. In certain embodiments, the DPP6 specific CAR is used to treat type 1 diabetes.

公开(公告)号：US20240182854A1

公开(公告)日：2024-06-06

申请号：US18450234

申请日：2023-08-15

申请人： The Trustees of the University of Pennsylvania ,  Regents of the University of Minnesota

发明人： James L. Riley ,  Carl H. June ,  Bruce R. Blazar ,  Keli Hippen

IPC分类号： C12N5/0783

CPC分类号： C12N5/0637 ,  C12N2500/32 ,  C12N2501/04 ,  C12N2501/2302 ,  C12N2501/51 ,  C12N2501/515

摘要： The present invention provides compositions and methods for expanding natural T regulatory cells (nTregs) without substantially sacrificing suppressive function of the cells. Accordingly, the invention provides uses of the expanded nTregs for cellular therapy.

公开(公告)号：US20230323394A1

公开(公告)日：2023-10-12

申请号：US18043462

申请日：2021-08-31

申请人： The Trustees of the University of Pennsylvania

发明人： James L. Riley

IPC分类号： C12N15/86 ,  C12N5/0783 ,  C07K14/005 ,  A61K39/00

CPC分类号： C12N15/86 ,  C12N5/0636 ,  C07K14/005 ,  A61K39/4611 ,  A61K39/4631 ,  C12N2500/90 ,  C12N2740/15052 ,  C12N2740/15043 ,  C12N2760/20222 ,  C12N2740/16022 ,  A61K2239/26 ,  A61K2239/21 ,  A61K2239/22 ,  A61K2239/13

摘要： The present disclosure provides compositions and methods for delivering a nucleic acid sequence encoding a chimeric antigen receptor (CAR) to an immune cell using a retroviral vector comprising an optimized Cocal vesiculovirus envelope protein.

公开(公告)号：US09555105B2

公开(公告)日：2017-01-31

申请号：US14247298

申请日：2014-04-08

申请人： THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA

发明人： James L. Riley ,  Carl H. June ,  Robert H. Vonderheide ,  Nicole Aqui ,  Megan M. Davis

IPC分类号： A61K48/00 ,  A61K39/39 ,  A61K39/21 ,  C12N5/078 ,  C12N5/0781 ,  C12N5/0783 ,  C12N5/09 ,  A61K47/48 ,  C12N15/86 ,  G01N33/50 ,  G01N33/569 ,  A61K39/12 ,  A61K35/12 ,  A61K39/00

CPC分类号： A61K39/39 ,  A61K39/12 ,  A61K39/21 ,  A61K47/642 ,  A61K2035/124 ,  A61K2039/5154 ,  A61K2039/5158 ,  A61K2039/55522 ,  A61K2039/55527 ,  A61K2039/55533 ,  C12N5/0634 ,  C12N5/0635 ,  C12N5/0636 ,  C12N5/0694 ,  C12N15/86 ,  C12N2501/23 ,  C12N2501/51 ,  C12N2501/515 ,  C12N2501/599 ,  C12N2502/99 ,  C12N2510/00 ,  C12N2740/15043 ,  G01N33/505 ,  G01N33/56972

摘要： The invention relates to novel artificial antigen presenting cells (aAPCs). The aAPC comprises at least one stimulatory ligand and at least one co-stimulatory ligand where the ligands each specifically bind with a cognate molecule on a T cell of interest, thereby mediating expansion of the T cell. The aAPC of the invention can further comprise additional molecules useful for expanding a T cell of interest. The aAPC of the invention can be used as an “off the shelf” APC that can be readily designed to expand a T cell of interest. Also, the aAPC of the invention can be used identify the stimulatory, co-stimulatory, and any other factors that mediate growth and expansion of a T cell of interest. Thus, the present invention provides powerful tools for development of novel therapeutics where activation and expansion of a T cell can provide a benefit.

摘要翻译： 本发明涉及新型人造抗原呈递细胞（aAPCs）。 aAPC包含至少一种刺激性配体和至少一种共刺激配体，其中配体各自特异性结合目标T细胞上的同源分子，从而介导T细胞的扩增。 本发明的aAPC可进一步包含可用于扩增感兴趣的T细胞的其它分子。 本发明的aAPC可以用作可以容易地设计用于扩大感兴趣的T细胞的“现成”APC。 此外，可以使用本发明的aAPC来鉴定刺激性，共刺激性和介导感兴趣的T细胞的生长和扩增的任何其它因素。 因此，本发明提供了用于开发新型治疗剂的有力工具，其中T细胞的活化和扩增可以提供益处。

公开(公告)号：US20160348072A1

公开(公告)日：2016-12-01

申请号：US15233397

申请日：2016-08-10

申请人： THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA

发明人： Carl H. June ,  James L. Riley ,  Marcela Maus ,  Anna Kaskel ,  Robert Vonderheide

IPC分类号： C12N5/0783 ,  A61K35/17 ,  C07K14/735

CPC分类号： C12N5/0636 ,  A61K35/17 ,  A61K2039/5158 ,  C07K14/70535 ,  C12N5/0634 ,  C12N2501/51 ,  C12N2501/515 ,  C12N2501/599 ,  C12N2502/99 ,  C12N2510/00 ,  C12N2510/04

摘要： Provided are a system and methods for selectively inducing expansion of a population of T cells in the absence of exogenous growth factors, such as lymphokines, and accessory cells for research purposes. The cell based expansion system and methods permit the long-term growth of CTLs, preferably human CTLs. In addition, T cell proliferation can be induced without the need for antigen, thus providing an expanded T cell population that is polyclonal with respect to antigen reactivity. Further provided are methods for using the system and methods to screen and identify antigens related to specific diseases or conditions, tumors, autoimmune disorders, or an infectious disease or pathogen, and to identify target molecule for research purposes, or for developing a vaccine based thereon.

摘要翻译： 提供了一种系统和方法，用于在没有外源性生长因子（例如淋巴因子）和用于研究目的的辅助细胞的情况下选择性诱导T细胞群的扩增。 基于细胞的扩增系统和方法允许CTL的长期生长，优选人CTL。 此外，可以在不需要抗原的情况下诱导T细胞增殖，从而提供关于抗原反应性的多克隆的扩增T细胞群。 进一步提供的是使用该系统和方法来筛选和鉴定与特定疾病或病症，肿瘤，自身免疫性疾病或感染性疾病或病原体相关的抗原的方法，并鉴定用于研究目的的靶分子或基于其开发疫苗 。

公开(公告)号：US12122820B2

公开(公告)日：2024-10-22

申请号：US16988415

申请日：2020-08-07

申请人： THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA

发明人： James L. Riley ,  Rachel Leibman ,  Aimee S. Payne ,  Christoph T. Ellebrecht ,  Michael C. Milone

IPC分类号： C07H21/04 ,  A61K35/17 ,  A61K38/17 ,  A61K39/42 ,  A61K45/06 ,  A61K48/00 ,  A61P31/18 ,  C07K14/705 ,  C07K14/725 ,  C07K14/73 ,  C07K16/10 ,  C12N15/63 ,  A01K67/00 ,  A61K39/00

CPC分类号： C07K14/70514 ,  A61K35/17 ,  A61K38/1774 ,  A61K39/42 ,  A61K45/06 ,  A61P31/18 ,  C07K14/7051 ,  C07K14/70517 ,  C07K14/70521 ,  C07K14/70578 ,  C07K16/1045 ,  A61K2039/505 ,  A61K2039/5158 ,  A61K2039/572 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/622 ,  C07K2317/76 ,  C07K2319/00 ,  C07K2319/02 ,  C07K2319/03 ,  C07K2319/30 ,  C07K2319/33

摘要： The present invention relates to compositions and methods for treating of a HIV infected mammal using a CD4 membrane-bound chimeric receptor or a HIV specific scFvs CARs. One aspect includes a modified T cell and pharmaceutical compositions comprising the modified cells for adoptive cell therapy and treating a disease or condition associated with HIV infection.

公开(公告)号：US20210275650A1

公开(公告)日：2021-09-09

申请号：US17133702

申请日：2020-12-24

申请人： The Trustees of the University of Pennsylvania ,  Regents of the University of Minnesota

发明人： James L. Riley ,  Carl H. June ,  Bruce R. Blazar ,  Keli Hippen

IPC分类号： A61K39/00 ,  C12N5/0783

摘要： The present invention provides methods and compositions for converting non-Tregs into Tregs. The converted Tregs are referred to as inducible Tregs (iTregs). The iTregs are useful for preventing, suppressing, blocking or inhibiting an immune response. For example the iTregs are useful for preventing rejection of a transplanted tissue in a human or other animal host, or protecting against graft vs host disease. The iTregs can also be used to treat autoimmune diseases.

公开(公告)号：US11001805B2

公开(公告)日：2021-05-11

申请号：US15986538

申请日：2018-05-22

申请人： The Trustees of the University of Pennsylvania

发明人： James L. Riley ,  Chrystal Paulos ,  Carl H. June ,  Bruce L. Levine

IPC分类号： A61K35/17 ,  C12N5/0783 ,  C07K14/705 ,  A61K39/00

摘要： The invention includes compositions and methods for generating and expanding therapeutic Th17 cells. The invention includes contacting T cells with a composition comprising a first agent that is capable of providing a primary activation signal to T cells and a second agent that is capable of activating ICOS on T cells in the presence of Th-17 polarizing agents.

公开(公告)号：US20170319684A1

公开(公告)日：2017-11-09

申请号：US15387199

申请日：2016-12-21

申请人： THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA

发明人： James L. Riley ,  Carl H. June ,  Robert H. Vonderheide ,  Nicole Aqui ,  Megan M. Davis

IPC分类号： A61K39/39 ,  A61K47/64 ,  G01N33/50 ,  A61K39/12 ,  A61K39/21 ,  C12N5/078 ,  C12N5/0781 ,  C12N5/0783 ,  C12N5/09 ,  C12N15/86 ,  G01N33/569 ,  A61K39/00 ,  A61K35/12

CPC分类号： A61K39/39 ,  A61K39/12 ,  A61K39/21 ,  A61K47/642 ,  A61K2035/124 ,  A61K2039/5154 ,  A61K2039/5158 ,  A61K2039/55522 ,  A61K2039/55527 ,  A61K2039/55533 ,  C12N5/0634 ,  C12N5/0635 ,  C12N5/0636 ,  C12N5/0694 ,  C12N15/86 ,  C12N2501/23 ,  C12N2501/51 ,  C12N2501/515 ,  C12N2501/599 ,  C12N2502/99 ,  C12N2510/00 ,  C12N2740/15043 ,  G01N33/505 ,  G01N33/56972

摘要： The invention relates to novel artificial antigen presenting cells (aAPCs). The aAPC comprises at least one stimulatory ligand and at least one co-stimulatory ligand where the ligands each specifically bind with a cognate molecule on a T cell of interest, thereby mediating expansion of the T cell. The aAPC of the invention can further comprise additional molecules useful for expanding a T cell of interest. The aAPC of the invention can be used as an “off the shelf’ APC that can be readily designed to expand a T cell of interest. Also, the aAPC of the invention can be used identify the stimulatory, co-stimulatory, and any other factors that mediate growth and expansion of a T cell of interest. Thus, the present invention provides powerful tools for development of novel therapeutics where activation and expansion of a T cell can provide a benefit.

公开(公告)号：US20160194616A1

公开(公告)日：2016-07-07

申请号：US14979055

申请日：2015-12-22

申请人： The Trustees of the University of Pennsylvania

发明人： Mariusz Wasik ,  James L. Riley ,  Qian Zhang ,  Fang Wei

IPC分类号： C12N9/12 ,  C12N15/85

CPC分类号： C12N9/12 ,  A01K2207/12 ,  A01K2267/0331 ,  C12N5/0694 ,  C12N9/1205 ,  C12N15/1137 ,  C12N15/85 ,  C12N2310/14 ,  C12N2501/727 ,  C12N2503/02 ,  C12N2510/00 ,  C12Y207/10001 ,  G01N33/5011 ,  G01N2333/91205

摘要： The present invention provides compositions and methods for transforming primary mammalian cells using an oncogenic form of ALK wherein the transformed cells display features of that of a corresponding tumor cell isolated from a cancer subject. The invention also provides a method for immortalizing normal CD4+ T lymphocytes with a lymphoma-characteristic form of ALK such as NPM-ALK.